TriSalus Study Shows PEDD Technology Improves Outcomes, Cuts Costs in Liver Cancer Treatments
Event summary
- TriSalus published a real-world study in the Journal of Comparative Effectiveness Research showing PEDD technology improved clinical outcomes in 603 patients with liver cancer compared to 16,210 non-PEDD patients.
- PEDD patients had higher baseline disease burden but demonstrated lower post-procedure fatigue rates (20.9% vs. 26.4%) and 61% fewer 30-day inpatient hospital visits for TACE procedures.
- The study found PEDD use led to $7,734 in mean per-patient charge avoidance, driven by reduced inpatient stays and clinical complications.
- Higher PEDD procedure volumes at facilities correlated with significantly lower lymphopenia rates and halved fatigue rates in patients with secondary liver metastases.
The big picture
TriSalus' study reinforces the strategic value of PEDD technology in enhancing drug delivery efficacy for liver cancer treatments, aligning with broader industry trends toward precision oncology and cost-effective healthcare solutions. The findings position TriSalus to potentially expand its market reach, particularly as healthcare systems seek innovative ways to improve patient outcomes while reducing economic burden. The integration of PEDD with standard-of-care therapies highlights a growing focus on combining technological advancements with existing medical practices to address complex solid tumors.
What we're watching
- Adoption Pace
- Whether TriSalus can sustain the growing adoption of PEDD technology across interventional oncology.
- Clinical Validation
- How subsequent studies will validate the long-term immune function benefits observed in PEDD patients.
- Partnership Strategy
- The pace at which TriSalus explores partnerships for developing its investigational immunotherapeutic, nelitolimod.
Related topics